Early experience of Sacubitril–Valsartan in heart failure with reduced ejection fraction in real‐world clinical setting

AIMS: Sacubitril/Valsartan (Sac/Val) was proven more effective than enalapril for symptomatic patients with heart failure (HF) with reduced ejection fraction (HFrEF). This study aimed to investigate eligibility, titration, and tolerability for Sac/Val in a real‐world clinical setting. METHODS AND RE...

Descripción completa

Detalles Bibliográficos
Autores principales: Nordberg Backelin, Charlotte, Fu, Michael, Ljungman, Charlotta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261574/
https://www.ncbi.nlm.nih.gov/pubmed/32030899
http://dx.doi.org/10.1002/ehf2.12644

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261574/
https://www.ncbi.nlm.nih.gov/pubmed/32030899
http://dx.doi.org/10.1002/ehf2.12644

Ejemplares similares